SAN JOSE, Calif., March 19, 2018 -- According to the latest report published by Credence Research, Inc. “Laxatives Market - Growth, Future Prospects and Competitive Analysis, 2018-2026,” the global laxatives market was valued at US$ 5,274.6 Mn in 2017, and is expected to reach US$ 8,734.2 Mn by 2026, expanding at a CAGR of 5.8% from 2018 to 2026.
Market Insights
The global laxatives market is projected to increase with a stable CAGR in the forecast period and the market is estimated to reach US$ 8,734.2 Mn by 2026. Rising prevalence of constipation globally, increased adoption of laxatives in the low economic countries, and growing awareness of the general population regarding gastrointestinal diseases are the factors contributing to the surge of the global laxatives market.
On the basis of drug type, the global laxatives market is segmented into docusate, psyllium, senna, bisacodyl, methylcellulose, polyethylene glycol 3350, and others. Each mentioned drug class has distinct mechanism for the treatment of constipation. Some of the aforementioned drugs act as bulk-forming agents while others act as stool softener or stimulating agents. In terms of market size, psyllium drug segment leads the global laxatives market for the year 2017.
On the basis of geographical demarcation, in 2017, North America dominated the global laxatives market due to increasing awareness of the general population regarding the gastrointestinal diseases. Demand from emerging economies of Middle East and Africa, and Asia Pacific is expected to be above the global benchmark during the forecast period. However, widespread acceptance of laxative drugs will still be challenged in these regions due to prevalent preference to home and traditional remedies. Key players in the global laxatives market include Boehringer Ingelheim Pharmaceuticals, Inc., Bayer AG, GlaxoSmithKline Plc, Braintree Laboratories, Inc., Purdue Pharma L.P., Procter & Gamble Company, and Sucampo Pharmaceuticals, Inc.
Despite the diversity of the available laxatives, there is an ongoing search for novel laxatives that will mitigate the dissatisfaction in a large group of patients. The development of newer compounds in this category is ongoing with some promising pipeline products in the IBS-C and OIC treatments. Analyzing the future pipeline of this market, BLI801, AJG555, Elobixibat, and Tenapanor are considered as the potential compounds for constipation treatment and the sales of mentioned drugs are estimated till 2026.
Browse the full report Laxatives Market - Growth, Future Prospects and Competitive Analysis, 2018-2026 report at http://www.credenceresearch.com/report/laxatives-market
About Us:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.
Contact:
Name: Chris Smith
Designation: Global Sales Manager
E-mail: [email protected]
Ph: 1-800-361-8290
Web: Credence Research
Read Our Blog: http://www.mobilecomputingtoday.co.uk/3512/global-laxatives-market-grow-5-6-cagr-2016-2022-credence-research/


Apple Restores Telegram to App Store After Content Policy Violation
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan
DeepSeek to Raise AI API Prices as Demand for New Models Surges
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 



